DeepMed Research

TYK Medicines, Inc

🇭🇰Hong Kong, China

Country: 🇭🇰Hong Kong, China

Ownership: -

Employees: -

Market Cap: -

Website: https://tyk.io

Clinical Trials

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: HR-positive, HER2-negative Advanced Breast Cancer

Interventions: Drug: TYK-00540

First Posted Date: 2025-04-29

Last Posted Date: 2025-04-29

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 180

Registration Number: NCT06950086

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Phase 2

Not yet recruiting

Conditions: NSCLC

Interventions: Drug: TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin
Drug: TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin

First Posted Date: 2024-11-04

Last Posted Date: 2024-12-30

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 60

Registration Number: NCT06672068

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

Phase 1

Completed

Conditions: NSCLC

Interventions: Drug: Itraconazole
Drug: Rifampicin

First Posted Date: 2024-02-13

Last Posted Date: 2024-12-30

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 48

Registration Number: NCT06255951

Locations: 🇨🇳
Yali Liu, Guangdong, Shantou, China

A Study of TYK-00540 in Adult Patients With Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: TYK-00540

First Posted Date: 2024-02-07

Last Posted Date: 2024-02-07

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 156

Registration Number: NCT06246071

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, China

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Phase 2

Recruiting

Conditions: Brain Metastases
NSCLC
EGFR Activating Mutation

Interventions: Drug: TY-9591
Drug: Osimertinib

First Posted Date: 2023-07-17

Last Posted Date: 2024-11-21

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 420

Registration Number: NCT05948813

Locations: 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TY-9591

First Posted Date: 2023-05-23

Last Posted Date: 2024-12-30

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 6

Registration Number: NCT05871905

Locations: 🇨🇳
Suzhou first people's hospital, Suzhou, Jiangsu, China

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: TY-2699a

First Posted Date: 2023-05-19

Last Posted Date: 2023-11-07

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 156

Registration Number: NCT05866692

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Phase 1

Recruiting

Conditions: Locally Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: TY-2136b

First Posted Date: 2023-03-15

Last Posted Date: 2023-04-24

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 282

Registration Number: NCT05769075

Locations: 🇺🇸
Oncology Consultants, Houston, Texas, United States
🇺🇸
Rhode Island Hospital, Brown University, Providence, Rhode Island, United States

A Study of TY-1091 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: RET-altered Papillary Thyroid Cancer
RET-altered Non Small Cell Lung Cancer
Neoplasms
Medullary Thyroid Cancer

Interventions: Drug: TY-1091

First Posted Date: 2023-01-09

Last Posted Date: 2024-01-30

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 248

Registration Number: NCT05675605

Locations: 🇨🇳
Jinlin Province Cancer Hosipital, Chang chun, Jilin, China

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Phase 3

Recruiting

Conditions: EGFR Activating Mutation
NSCLC

Interventions: Drug: TY-9591
Drug: Osimertinib
Drug: placebo TY-9591
Drug: placebo Osimertinib

First Posted Date: 2022-05-19

Last Posted Date: 2024-01-30

Lead Sponsor: TYK Medicines, Inc

Target Recruit Count: 680

Registration Number: NCT05382728

Locations: 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy